{"id":3599,"date":"2026-10-03T09:00:00","date_gmt":"2026-10-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3599"},"modified":"2026-10-03T22:08:52","modified_gmt":"2026-10-04T02:08:52","slug":"saturday-rounds-week-of-september-27-october-2-2026","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3599","title":{"rendered":"Saturday Rounds: Week of September 27\u2013October 2, 2026"},"content":{"rendered":"

\"\"<\/p>\n

Evidence before optionality — a first-line label expansion backed by an 80% risk reduction led the week, large pharma wrote roughly $2.3 billion of upfront checks for early-stage modalities, and two programs that could not hold their effect — uniQure’s AMT-130 and Foghorn’s FHD-909 — were punished by 64% and 49% single-session drops.<\/strong><\/p>\n

Weekly Biotech Signal Review · Completed reporting week: September 27–October 2, 2026 · Published October 3, 2026<\/p>\n

Report at a glance: Evidence set the price — the FDA’s first-line approval of pirtobrutinib in CLL\/SLL, $2.287 billion of current upfront or selection cash across five licensing events, Phase 3 wins for Kodiak and Mirum, and sharp single-session punishments for uniQure and Foghorn while XBI slipped just 0.39%.<\/p>\n

The Lede<\/h3>\n

The week’s strongest signal was not its largest deal. On October 2 the FDA approved Eli Lilly’s pirtobrutinib (Jaypirca) for previously untreated CLL\/SLL without a known 17p deletion, on the strength of BRUIN CLL-313, in which the non-covalent BTK inhibitor cut the risk of progression or death by 80% against bendamustine–rituximab. The broader message was just as clear. Differentiated modalities drew very large checks — Sanofi’s $1 billion upfront to expand its Regeneron alliance, Novartis’s $575 million for an mRNA-encoded CD19×CD3 engager, Merck’s $400 million for a preclinical KRAS G12D molecular glue and Novo’s $300 million for a Phase 1-ready oral GLP-1\/GIP agonist — but human efficacy and durability, not mechanistic novelty alone, set the price in public markets. uniQure fell about 64% when its four-year Huntington’s composite result lost statistical significance, and Foghorn fell 49% in one session when Lilly and Foghorn stopped FHD-909. Indices barely moved: XBI slipped 0.39%, IBB fell 2.14% and SPY fell 0.22%.<\/p>\n\n\n\n
Signal Importance<\/th>\nSignal Direction<\/th>\nConfidence in Facts<\/th>\nConfidence in Interpretation<\/th>\n<\/tr>\n
5 of 5<\/td>\nPositive for the approved population<\/td>\nHigh<\/td>\nModerate<\/td>\n<\/tr>\n<\/table>\n

Weekly validation gate: importance is 5\/5 because the evidence is randomized, regulatory-grade and moves a noncovalent BTK inhibitor into the front-line setting. Interpretation is moderate because chemoimmunotherapy is no longer the most demanding comparator in many markets, the label excludes known 17p deletion, and the trial does not establish superiority over venetoclax–obinutuzumab or second-generation covalent BTK inhibitors.<\/em><\/p>\n

Signal of the Week: Pirtobrutinib Moves to First-Line CLL\/SLL<\/h3>\n

BRUIN CLL-313 reported a progression-free-survival hazard ratio of 0.20 (95% CI 0.11–0.37) for pirtobrutinib against bendamustine–rituximab, an overall response rate of 94%, and the label now covers previously untreated adults with no known 17p deletion. Jaypirca was previously approved only after a covalent BTK inhibitor, so this is the first approval of a non-covalent BTK inhibitor in the first-line setting. It converts pirtobrutinib from a resistance-setting tool into a front-line competitor.<\/p>\n

The strongest counterargument is comparator relevance. Bendamustine–rituximab is a weak benchmark in markets where fixed-duration venetoclax–obinutuzumab or covalent BTK inhibitors are standard, so a hazard ratio of 0.20 shows that pirtobrutinib clearly beats an older regimen, not that it displaces the current leaders. The exclusion of known del(17p) further narrows the population. The approval is a strong, well-evidenced label expansion; its competitive consequence depends on head-to-head or indirect evidence the trial does not provide. Primary source<\/a><\/p>\n

The Week in Five<\/h3>\n

Regulatory<\/strong> — The FDA approved pirtobrutinib for first-line CLL\/SLL (Oct 2), AbbVie’s JUVMO (tavapadon), the first selective D1\/D5 dopamine agonist, for Parkinson’s disease (Sep 28), and Bristol Myers Squibb’s CAMZYOS for pediatric obstructive HCM in patients 12 to 18 (Sep 30; SCOUT-HCM, 44 adolescents, outflow-gradient change of −49.4 vs −1.8 mmHg). Atara and Pierre Fabre resubmitted the tabelecleucel BLA after two Complete Response Letters (Sep 30) — a resubmission, not an approval.<\/p>\n

Clinical<\/strong> — Kodiak’s Phase 3 DAYBREAK met its primary endpoint, with Zenkuda and KSI-501 each non-inferior to aflibercept (Sep 28; 54% of Zenkuda patients reached a 6-month interval under strict treat-to-dry criteria). Mirum’s Phase 3 AZURE-1 of brelovitug in hepatitis delta met its week-24 endpoint (56% at 300 mg weekly and 45% at 900 mg every four weeks, versus 0% delayed treatment). Adicet’s allogeneic gamma-delta CAR-T prula-cel produced drug-free lupus responses (Sep 28). uniQure’s four-year AMT-130 composite result lost significance (Sep 29).<\/p>\n

Deals<\/strong> — Five license or collaboration events carried $2.287 billion in current upfront or selection cash: Merck–SciBrunch, Novo–Hengrui, Wave–GSK, Sanofi–Regeneron and Novartis–Abogen. Separately, AstraZeneca agreed to invest $2 billion in convertible preferred equity in Summit Therapeutics alongside a clinical collaboration; that is strategic equity, not deal consideration.<\/p>\n

Platform<\/strong> — Monte Rosa’s MRT-8102 gave human proof of NEK7 degradation (median 80–90%) with a median 85% hsCRP reduction in 108 participants, while Foghorn’s FHD-909 showed that selective target engagement cannot rescue insufficient efficacy.<\/p>\n

China<\/strong> — China-originated SPR2015 (Merck, $400 million upfront), HRS-1596 (Novo, $300 million) and ABO2203 (Novartis, $575 million) together attracted $1.275 billion upfront, confirming China as an origin market for modalities and assets rather than only a regional commercialization venue.<\/p>\n

The Analyst’s Take<\/h3>\n

Observed pattern: the week rewarded mechanisms only after they crossed an evidence threshold. Pirtobrutinib reached label expansion through randomized benefit; Adicet paired response with immunosuppressant-free follow-up and an outpatient pivotal path; Kodiak and Mirum delivered Phase 3 wins; and Monte Rosa showed dose-dependent target degradation in humans. Against those positives, AMT-130’s four-year composite comparison was non-significant, FHD-909 stopped for insufficient efficacy, and tabelecleucel remained a third submission rather than a regulatory resolution.<\/p>\n

Explicit inference: large-pharma buyers appear willing to pay for access to modality optionality before efficacy is known — $400 million upfront for a preclinical molecule, $575 million for an early-Phase 1 mRNA engager plus platform options, $300 million for a Phase 1-ready oral agonist. That does not make capital indiscriminate: the headline totals are mostly contingent milestones, and public markets punished fragile effect estimates immediately. uniQure attributed its miss to survivor bias in the ENROLL-HD external control, in which 53% of control patients had dropped out by month 48; on the functional measure (Total Functional Capacity) the high-dose effect remained nominally significant. That is a company explanation and a secondary endpoint, not a rescue of the primary result.<\/p>\n

Competing interpretation: this could be simple end-of-quarter deal timing rather than a durable shift toward mechanism-plus-evidence portfolios. The thesis strengthens if buyers keep paying substantial upfront cash for assets with differentiated human pharmacology and if Adicet, Monte Rosa and Abogen reproduce efficacy with acceptable durability. It weakens if deals remain option-heavy, if pivotal programs fail to replicate early biomarkers, or if manufacturing, cytokine, immunogenicity or genotoxicity liabilities erase the convenience advantage of in vivo and off-the-shelf platforms.<\/p>\n

Evidence chain: Pirtobrutinib approval<\/a> · Adicet prula-cel<\/a> · Kodiak DAYBREAK<\/a> · Mirum AZURE-1<\/a> · uniQure AMT-130<\/a> · Monte Rosa MRT-8102<\/a> · Foghorn FHD-909<\/a><\/em><\/p>\n

Evidence Classification<\/h3>\n\n\n\n
Verified facts<\/th>\nCompany claims<\/th>\nExplicit inference<\/th>\n<\/tr>\n
Approval dates, trial counts, endpoint values, deal terms and financing amounts were checked against FDA.gov, company releases, SEC filings and named trade press.<\/td>\nuniQure’s survivor-bias explanation, Kodiak’s “potential new standard-of-care profile,” and platform-differentiation language in deal releases remain sponsor positions.<\/td>\n“Evidence before optionality” as the week’s organizing theme, and the reading that markets priced cleaner causal evidence, are interpretations, not findings.<\/td>\n<\/tr>\n<\/table>\n

Market & Capital Pulse<\/h3>\n

Observed market facts.<\/strong> Measurement window: Friday, September 25 close to Friday, October 2 close, confirmed against live closes. XBI fell 0.39% (155.03 to 154.43), IBB fell 2.14% (209.77 to 205.29), and SPY fell 0.22% (771.35 to 769.64); the S&P 500 index fell about 0.27% on the week. Equal-weighted XBI therefore roughly tracked the broad market while large-cap-heavy IBB lagged by almost two points. Company-level dispersion was more informative than the indices: uniQure lost about 64% and Foghorn 49% on their respective news, while Kodiak rose roughly 150% on DAYBREAK. Prices are market observations, not confirmation of any scientific reading.<\/p>\n

Capital and strategic appetite.<\/strong> Confirmed private financings were selective: Link Cell Therapies added $30 million to its Series A (bringing it to $90 million) as it dosed its first patient with a logic-gated CAR-T; AnaCardio raised €62.5 million in Series B (co-led by Novo Holdings and the Ljungström family office) for its ghrelin-agonist heart-failure drug AC01; and TriGemX Bio, formerly Kallyope, closed $94 million to run Phase 3 trials of its oral TRPM8 blocker elismetrep in migraine. No new conventional IPO priced, but ADARx — whose upsized IPO was covered in last week’s edition — closed on September 28 with its underwriters’ option fully exercised, lifting IPO gross proceeds from $446.3 million to about $513.2 million, or about $602.5 million with AbbVie’s concurrent private placement.<\/p>\n

Inference.<\/strong> Licensing appetite was stronger than public issuance: $2.287 billion of current upfront or selection payments across the five alliances, against roughly $18.6 billion of conditional milestone capacity. Capital is available but priced for risk transfer — buyers pay meaningful cash for platform access while pushing most value into contingent payments.<\/p>\n

Market and capital verification: XBI<\/a> · IBB<\/a> · SPY<\/a> · S&P 500 weekly snapshot<\/a> · ADARx<\/a> · Link<\/a> · AnaCardio<\/a> · TriGemX<\/a><\/em><\/p>\n

Deal Appetite and Restructuring<\/h3>\n

The five license and collaboration events were Merck–SciBrunch (SPR2015, oral KRAS G12D molecular glue; $400 million upfront, up to $1.73 billion in milestones), Novo–Hengrui (HRS-1596, once-weekly oral GLP-1\/GIP; $300 million upfront, up to $2.6 billion in total), Wave–GSK (GSK selected a hepatology siRNA candidate, triggering a $12 million milestone), Sanofi–Regeneron ($1 billion upfront, up to $7 billion in further milestones across four long-acting immunology antibodies, 50:50 profit split) and Novartis–Abogen (ABO2203; $575 million upfront, up to about $7.2 billion in milestones across the program and optioned assets). Summing the four deals with disclosed totals gives about $20.5 billion of stated maximum value; adding Wave’s per-program milestone potential brings it to roughly $20.9 billion.<\/p>\n

One material restructuring occurred. Foghorn and Lilly decided not to advance FHD-909 after Phase 1 dose-escalation review, ended the partnered selective SMARCA2 degrader program, and Foghorn cut about 40% of its workforce, leaving roughly 65 employees, to extend runway into the second half of 2029 around its proprietary EP300 and CBP degrader programs. Foghorn shares fell 49% in one session.<\/p>\n

Deal verification: Merck\u2013SciBrunch<\/a> · Novo\u2013Hengrui<\/a> · Wave\u2013GSK<\/a> · Sanofi\u2013Regeneron<\/a> · Novartis\u2013Abogen<\/a> · AstraZeneca\u2013Summit<\/a><\/em><\/p>\n

By the Numbers<\/h3>\n\n\n\n\n\n\n\n\n\n\n
Category<\/th>\nCount<\/th>\nCapital \/ measure<\/th>\nWhat is included<\/th>\n<\/tr>\n
Major regulatory actions<\/td>\n4<\/td>\n3 approvals; 1 BLA resubmission<\/td>\nPirtobrutinib first-line CLL\/SLL; JUVMO; CAMZYOS pediatric; tabelecleucel resubmission.<\/td>\n<\/tr>\n
Verified clinical readouts<\/td>\n6<\/td>\n3 Phase 3-linked<\/td>\nDAYBREAK; AZURE-1; AMT-130 (48 months); prula-cel; MRT-8102; FHD-909 stop.<\/td>\n<\/tr>\n
License \/ collaboration events<\/td>\n5<\/td>\n$2.287B current; ~$20.9B max<\/td>\nMerck–SciBrunch; Novo–Hengrui; Wave–GSK; Sanofi–Regeneron; Novartis–Abogen.<\/td>\n<\/tr>\n
Strategic equity (separate)<\/td>\n1<\/td>\n$2B<\/td>\nAstraZeneca–Summit convertible preferred; excluded from deal totals.<\/td>\n<\/tr>\n
Private rounds<\/td>\n3<\/td>\n$124M + €62.5M<\/td>\nLink ($30M incremental; $90M cumulative); TriGemX ($94M); AnaCardio (€62.5M).<\/td>\n<\/tr>\n
IPO \/ follow-on<\/td>\n0 new<\/td>\nADARx option exercised<\/td>\nADARx IPO proceeds rose to ~$513.2M gross (~$602.5M with AbbVie placement) on Sep 28; priced the prior week.<\/td>\n<\/tr>\n
Material restructuring<\/td>\n1<\/td>\n~40% workforce<\/td>\nFoghorn after FHD-909 and the partnered SMARCA2 program stopped.<\/td>\n<\/tr>\n
Leadership changes<\/td>\nVerified: 1 company<\/td>\n—<\/td>\nLink Cell Therapies expanded its executive team; additional TriGemX changes in the reference file were not independently verified.<\/td>\n<\/tr>\n<\/table>\n

Primary verification: FDA<\/a> · AbbVie<\/a> · BMS<\/a> · Atara<\/a> · Kodiak<\/a> · Mirum<\/a> · Adicet<\/a> · uniQure<\/a> · Monte Rosa<\/a> · Foghorn<\/a><\/em><\/p>\n

Watching Next Week<\/h3>\n

Resolution of last week’s calendar: Kodiak’s DAYBREAK read out on September 28 and met its primary endpoint; ADARx’s IPO closed on September 28 with its option fully exercised. The World Muscle Society Congress in Hiroshima runs through October 3, and the October 1 FDA VRBPAC influenza-strain meeting’s outcome was not independently verified for this edition.<\/p>\n\n\n\n\n\n\n
Date<\/th>\nConfirmed catalyst<\/th>\nEvidence status<\/th>\n<\/tr>\n
Oct 5–7<\/td>\nCell & Gene Meeting on the Mesa, Phoenix<\/td>\nConfirmed organizer dates; company presentations and partnering, not prespecified trial readouts.<\/td>\n<\/tr>\n
Oct 7–9<\/td>\nBioJapan \/ Regenerative Medicine JAPAN, Yokohama<\/td>\nConfirmed organizer dates; Asia partnering, licensing and manufacturing signals.<\/td>\n<\/tr>\n
Oct 5–9<\/td>\nNo sponsor-confirmed high-priority PDUFA or advisory committee identified<\/td>\nNegative finding from the calendars reviewed; no unsourced dates substituted.<\/td>\n<\/tr>\n
No fixed date<\/td>\nMirum AZURE-4 Phase 3 HDV readout<\/td>\nCompany guidance for Q4 2026; not a confirmed next-week event.<\/td>\n<\/tr>\n<\/table>\n

Calendar verification: Cell & Gene Meeting on the Mesa<\/a> · BioJapan<\/a> · Mirum<\/a><\/em><\/p>\n

What Would Change Our View<\/h3>\n

Upgrade<\/strong> — Randomized or prespecified replication of durable, drug-free responses for allogeneic autoimmune CAR-T or in vivo immune reset, with manageable infection and cytokine risk.<\/p>\n

Downgrade<\/strong> — Loss of effect after immune reconstitution, target recovery or longer follow-up — or manufacturing variability that erodes the access advantage of off-the-shelf and in vivo approaches.<\/p>\n

Falsify<\/strong> — A pattern in which large upfront modality deals repeatedly fail before proof of concept while conventional comparators outperform on efficacy, safety and total cost of care.<\/p>\n

Evidence Base<\/h3>\n

Sources are listed in order of first citation. Two corrections to the reference material used for this edition: uniQure’s single-session decline was reported at about 64% (not about 36%), and items for which no primary source could be found (a WAS gene therapy readout, a ROR1 post–CAR-T study, GLOW and zilovertamab) were left out rather than carried forward.<\/p>\n

    \n
  1. FDA, FDA approves pirtobrutinib for previously untreated CLL or SLL (Oct 2, 2026)<\/a><\/li>\n
  2. OncoDaily, FDA Approves Pirtobrutinib for First-Line CLL\/SLL Without 17p Deletion<\/a><\/li>\n
  3. AbbVie, U.S. FDA Approves JUVMO (tavapadon) for Parkinson’s Disease (Sep 28, 2026)<\/a><\/li>\n
  4. Bristol Myers Squibb, FDA Approves Expanded Indication for CAMZYOS in Adults and Pediatric Patients<\/a><\/li>\n
  5. CGTLive \/ Atara, Tabelecleucel BLA resubmitted to FDA (Sep 30, 2026)<\/a><\/li>\n
  6. Kodiak Sciences, Zenkuda and tabirafusp-ted meet primary endpoints in pivotal DAYBREAK trial (Sep 28, 2026)<\/a><\/li>\n
  7. Mirum Pharmaceuticals, Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug (Sep 28, 2026)<\/a><\/li>\n
  8. Adicet Bio, Positive Safety and Efficacy Data from Prula-cel in Lupus (Sep 28, 2026)<\/a><\/li>\n
  9. uniQure, Additional Data from Phase I\/II Studies of AMT-130 in Huntington’s Disease (Sep 29, 2026)<\/a><\/li>\n
  10. Yahoo Finance, uniQure Shares Fall 64% After 48-Month AMT-130 Update<\/a><\/li>\n
  11. Monte Rosa Therapeutics, Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study (Oct 1, 2026)<\/a><\/li>\n
  12. Pharmaceutical Executive, Foghorn and Eli Lilly Halt FHD-909 Development<\/a><\/li>\n
  13. Investing.com, Foghorn ends FHD-909 program, cuts 40% of workforce<\/a><\/li>\n
  14. Merck, Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015 (Sep 28, 2026)<\/a><\/li>\n
  15. Novo Nordisk \/ Hengrui, Exclusive License Agreement for HRS-1596 (Sep 29, 2026)<\/a><\/li>\n
  16. Wave Life Sciences, GSK’s Selection of siRNA Program to Transition to GSK (Sep 30, 2026)<\/a><\/li>\n
  17. Bloomberg, Sanofi, Regeneron Seal Deeper Partnership Worth Up to $8 Billion (Oct 1, 2026)<\/a><\/li>\n
  18. Endpoints News, Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront<\/a><\/li>\n
  19. AstraZeneca, Strategic Equity Investment and Clinical Collaboration with Summit Therapeutics (Sep 28, 2026)<\/a><\/li>\n
  20. Link Cell Therapies, Clinical Dosing, Expanded Leadership and Upsized $90 Million Series A (Sep 28, 2026)<\/a><\/li>\n
  21. AnaCardio, \u20ac62.5 Million Series B Financing (Sep 30, 2026)<\/a><\/li>\n
  22. TriGemX Bio, $94M Financing and Initiation of Phase 3 Trials for Elismetrep<\/a><\/li>\n
  23. StockTitan, ADARx closes IPO option as gross proceeds reach ~$513M<\/a><\/li>\n
  24. StockAnalysis.com, XBI price and close (Oct 2, 2026)<\/a><\/li>\n
  25. StockAnalysis.com, IBB price and close (Oct 2, 2026)<\/a><\/li>\n
  26. StockAnalysis.com, SPY price and close (Oct 2, 2026)<\/a><\/li>\n
  27. ETF Trends, S&P 500 Snapshot: Stocks Rally to Close Out Flat Week<\/a><\/li>\n
  28. Cell & Gene Meeting on the Mesa, October 5\u20137, 2026<\/a><\/li>\n
  29. BioJapan 2026, Yokohama, October 7\u20139<\/a><\/li>\n<\/ol>\n

    Until next Saturday: follow the evidence, not the noise.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Evidence before optionality \u2014 a first-line label expansion backed by an 80% risk reduction led the week, large pharma wrote roughly $2.3 billion of upfront checks for early-stage modalities, and two programs that could…<\/p>\n","protected":false},"author":1,"featured_media":3602,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[250,251,249],"class_list":["post-3599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weekly-market-insight","tag-biotech-markets","tag-ma","tag-weekly-digest"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3599"}],"version-history":[{"count":3,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3599\/revisions"}],"predecessor-version":[{"id":3603,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3599\/revisions\/3603"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3602"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}